Dihexa: A Tracking Guide for a Preclinical Nootropic

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small molecule derived from angiotensin IV, developed in academic labs as a potential treatment for cognitive decline. The interesting mechanism is that it appears to potentiate hepatocyte growth factor (HGF) signalling through the c-Met receptor, which is involved in forming new synaptic connections. The important caveat is that essentially all of the encouraging data is preclinical.

This guide is not a recommendation. It is a framework for logging cleanly if you have decided, with a physician, to experiment with something that is still firmly in the research stage.

What people claim it does

• Promotes synaptogenesis (formation of new synapses) in animal models
• Improves performance on memory tasks in rodent models of dementia
• Marketed informally as an extremely potent "nootropic"

The honest evidence picture

• The cognitive benefits are demonstrated in rats, not in controlled human trials
• Long-term human safety is unknown
• Because the mechanism encourages cell growth and angiogenesis, there is a legitimate theoretical concern about tumour promotion that has not been ruled out
• There is no established human dose, route, or cycle

That last point matters: any protocol you see online is improvised, not validated.

Typical protocol shape (as reported, not endorsed)

• Very small daily doses, often reported in single-digit milligrams or less
• Oral or subcutaneous routes both circulate in self-experimenter logs
• Short, intermittent cycles rather than continuous use

What to track daily

• Dose, time, route
• Mental clarity and focus (0-10)
• Word recall and "tip of the tongue" frequency
• Headache, visual changes, or pressure
• Mood and irritability
• Sleep onset and quality

What to track weekly

• A consistent cognitive task (same app, same time of day) for an objective trend line
• Any new skin lesions, lumps, or moles changing - given the growth-factor mechanism, document these and show a doctor
• Subjective overall well-being

Realistic expectations

• You are an n-of-1 with no human efficacy benchmark to compare against
• Placebo and novelty effects are strong with nootropics; a baseline week and a blinded-ish comparison are the only defences
• "More potent" claims you read online are extrapolated from animal potency, not human outcomes

Common mistakes

• Treating animal-model results as if they were human results
• Ignoring the tumour-promotion theoretical risk because it is inconvenient
• Stacking with three other nootropics so no signal is attributable
• No baseline cognitive measure, so "it works" is pure vibe

A tracking template

• Week 0: baseline cognitive task daily, no compound
• Weeks 1-4: protocol, daily subjective logs plus the same cognitive task
• Weeks 5-6: washout, keep logging to see whether anything persists

Safety notes

The single biggest issue is that this is preclinical. Long-term safety is unknown and the growth-promoting mechanism warrants real caution, especially for anyone with a personal or family history of cancer. This is not an approved nootropic anywhere, and product purity from research suppliers is unverifiable without testing.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.